Eisai Korea Inc.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Active:4

Completed:26

Trial Phases

2 Phases

Phase 1:4

Phase 4:14

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials

Phase 4

14 (77.8%)

Phase 1

4 (22.2%)

A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

Phase 4

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Filgotinib Maleate

First Posted Date: 2025-05-09

Last Posted Date: 2025-06-05

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 94

Registration Number: NCT06964113

Locations: 🇰🇷
Eisai Site #13, Busan, Korea, Republic of
🇰🇷
Eisai Site #8, Busan, Korea, Republic of
🇰🇷
Eisai Site #7, Chungnam, Korea, Republic of

and more 11 locations

A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease

Recruiting

Conditions: Alzheimer's Disease

First Posted Date: 2025-02-06

Last Posted Date: 2025-05-31

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 3000

Registration Number: NCT06810960

Locations: 🇺🇸
Eisai Trial Site #1, Nutley, New Jersey, United States

A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis

Phase 4

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Filgotinib Maleate

First Posted Date: 2024-10-03

Last Posted Date: 2025-07-09

Lead Sponsor: Eisai Korea Inc.

Target Recruit Count: 150

Registration Number: NCT06625242

Locations: 🇰🇷
Eisai site #11, Anyang-si, Korea, Republic of
🇰🇷
Eisai site #01, Busan, Korea, Republic of
🇰🇷
Eisai site #09, Daegu, Korea, Republic of

and more 12 locations